全文获取类型
收费全文 | 904篇 |
免费 | 42篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 19篇 |
妇产科学 | 12篇 |
基础医学 | 55篇 |
口腔科学 | 3篇 |
临床医学 | 41篇 |
内科学 | 279篇 |
皮肤病学 | 18篇 |
神经病学 | 272篇 |
特种医学 | 5篇 |
外科学 | 110篇 |
综合类 | 4篇 |
预防医学 | 38篇 |
眼科学 | 5篇 |
药学 | 32篇 |
肿瘤学 | 46篇 |
出版年
2023年 | 3篇 |
2022年 | 5篇 |
2021年 | 16篇 |
2020年 | 9篇 |
2019年 | 14篇 |
2018年 | 19篇 |
2017年 | 12篇 |
2016年 | 18篇 |
2015年 | 7篇 |
2014年 | 36篇 |
2013年 | 46篇 |
2012年 | 69篇 |
2011年 | 80篇 |
2010年 | 35篇 |
2009年 | 33篇 |
2008年 | 48篇 |
2007年 | 47篇 |
2006年 | 57篇 |
2005年 | 46篇 |
2004年 | 35篇 |
2003年 | 34篇 |
2002年 | 33篇 |
2001年 | 30篇 |
2000年 | 29篇 |
1999年 | 28篇 |
1998年 | 6篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1994年 | 6篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 18篇 |
1990年 | 10篇 |
1989年 | 16篇 |
1988年 | 19篇 |
1987年 | 6篇 |
1986年 | 9篇 |
1985年 | 11篇 |
1984年 | 8篇 |
1983年 | 7篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1976年 | 3篇 |
1973年 | 3篇 |
1972年 | 1篇 |
1967年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有948条查询结果,搜索用时 15 毫秒
11.
Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. 总被引:3,自引:0,他引:3
E Kostadima S Tsiodras E I Alexopoulos A G Kaditis I Mavrou N Georgatou A Papamichalopoulos 《The European respiratory journal》2004,23(5):714-717
A randomised double-blind placebo-controlled study was designed to evaluate the effects of a semisynthetic macrolide antibiotic, clarithromycin, on bronchial hyperresponsiveness to methacholine in patients with a diagnosis of asthma. Adult asthma patients undergoing treatment with budesonide 400 microg b.i.d. and salbutamol 200 microg p.r.n. less than twice weekly were studied. Arm A (16 males/six females, aged 48 +/- 16 yrs) received clarithromycin 250 mg b.i.d. for 8 weeks, arm B (eight males/12 females, aged 42 +/- 12 yrs) clarithromycin 250 mg t.id. and arm C (six males/15 females, aged 41 +/- 16 yrs) placebo dextrose tablets. Bronchial hyperresponsiveness was quantified by measurement of the provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second (PD20). Median (interquartile range) PD20 in the three groups before and after treatment with clarithromycin were: arm A: 0.3 (0.1-1) and 1.3 (0.6-2) mg; arm B: 0.4 (0.1-0.9) and 2 (2-2) mg; and arm C: 0.4 (0.1-0.9) and 0.3 (0.1-0.6) mg, respectively. Serum free cortisol levels were determined and remained unchanged from baseline in the clarithromycin-treated patients. It is concluded that clarithromycin reduces the degree of bronchial hyperresponsiveness in patients with asthma. 相似文献
12.
13.
14.
Alastair J. Flint Anthony J. Rothschild Ellen M. Whyte George S. Alexopoulos Benoit H. Mulsant Patricia Marino Samprit Banerjee Cristina D. Pollari Yiyuan Wu Aristotle N. Voineskos Barnett S. Meyers 《The American journal of geriatric psychiatry》2021,29(7):645-654
ObjectiveTo examine the effect of older versus younger age on change in anthropometric and metabolic measures during extended treatment of psychotic depression with sertraline plus olanzapine.MethodsTwo hundred and sixty-nine men and women aged 18–85 years with an episode of psychotic depression were treated with open-label sertraline plus olanzapine for up to 12 weeks. Participants who remained in remission following an 8-week stabilization phase were eligible to participate in a 36-week randomized controlled trial (RCT) that compared the efficacy and tolerability of sertraline plus olanzapine with sertraline plus placebo. Weight, waist circumference and plasma lipids, glucose, HbA1c, and insulin were measured at regular intervals during the acute, stabilization and randomized phases of the study. Linear mixed models were used to analyze the trajectories of anthropometric and metabolic measures.ResultsParticipants aged 60 years or older experienced less weight gain and less increase in cholesterol during the combined acute and stabilization phases of the study compared with those aged 18–59 years. At the acute-stabilization termination visit, mean weight in older participants was 6.5 lb. less than premorbid weight, whereas it was 17.9 lb. more than premorbid weight in younger participants. In the RCT, there was a significant interaction of treatment and age group for the trajectory of weight, but the post hoc tests that compared age groups within each treatment arm were not statistically significant. There were no clinically significant differences between younger and older participants in glycemic measures.ConclusionOlder patients with psychotic depression experienced less increase in weight and total cholesterol than their younger counterparts during acute and stabilization treatment with sertraline plus olanzapine. In the older group, weight gained during the acute and stabilization phases appeared to be partial restoration of weight lost during the index episode of depression, whereas weight gain in younger participants was not. 相似文献
15.
Monique A. Pimontel Nili Solomonov Lauren Oberlin Theodora Kanellopoulos Jennifer N. Bress Matthew J. Hoptman George S. Alexopoulos Faith M. Gunning 《The American journal of geriatric psychiatry》2021,29(3):241-248
ObjectiveApathy is common in late-life depression and is associated with poor response to antidepressant drugs. In depressed older adults, apathy may be characterized by neuroanatomical abnormalities of the salience network. The current study examined whether cortical thickness of select salience network structures predicted change in apathy following a 12-week treatment with escitalopram.MethodsA sample of 46 older adults with major depressive disorder received 12 weeks of escitalopram treatment at a daily target dose of 20 mg. All participants underwent a structural brain MRI scan at baseline, and cortical thickness was estimated in key cortical nodes of the salience network: the caudal anterior cingulate cortex and the insula. We measured baseline and post-treatment symptoms using the Apathy Evaluation Scale and the Hamilton Depression Rating Scale.ResultsA thicker insula at baseline predicted reduction in apathy symptoms following 12 weeks of treatment with escitalopram, even when controlling for age, baseline depression severity and change in depressive symptoms.ConclusionReduced insular thickness predicted residual apathetic symptoms following escitalopram treatment. These results converge with our previous findings of abnormal functional connectivity of the insular cortex in older depressed individuals with apathy. Older depressed adults with apathy may benefit from alternative treatment approaches or augmentative interventions that target abnormalities of the salience network. 相似文献
16.
17.
18.
A Lipson N Alexopoulos GR Hartlage C Arepalli A Oeser A Bian T Gebretsadik A Shintani AE Stillman CM Stein P Raggi 《Atherosclerosis》2012,223(2):389-393
ObjectiveMorbidity and mortality secondary to premature cardiovascular disease (CVD) in systemic lupus erythematosus (SLE) remain significant issues. The pathogenesis of CVD in SLE patients has not been fully explored. Epicardial adipose tissue (EAT) is believed to contribute to atherosclerosis development, through a paracrine and systemic inflammatory effect. We measured EAT volume in 162 SLE patients and 86 matched controls to assess the association of EAT with markers of atherosclerosis, cardiovascular risk and immunoactivation.MethodsClinical and laboratory characteristics collected included anthropomorphic measures, disease activity and damage indices, blood pressure measurement, lipid profile, inflammatory indices, adipokine levels and measures of adiposity. Coronary artery calcium (CAC) and EAT volume were measured using non-contrast cardiac computed tomography.ResultsEAT volume was greater in patients with SLE [(mean ± SD) 96.8 ± 45.9 cm3] than controls (78.2 ± 40.7 cm3; P = 0.001). The EAT volume was 31% larger (95% CI, 16.5%–47.4%) in SLE patients than controls (P < 0.001 adjusted for age, sex, and race; after additional adjustment for waist circumference P = 0.007). Within SLE patients, after adjusting for age, race, sex, and waist circumference, EAT volume was associated with cumulative corticosteroid dose (P = 0.007), current corticosteroid use (P < 0.001), HDL cholesterol (P = 0.033), and triglycerides (P = 0.005). EAT was significantly correlated with CAC score (P < 0.001), but the association was attenuated after adjustment for Framingham risk score (P = 0.051).ConclusionThe increased EAT volume seen in SLE patients is associated with corticosteroid use. Corticosteroids could have adverse cardiovascular effects in SLE via an increase in EAT volume, a marker of risk in the general population. 相似文献
19.
Athyros VG Elisaf MS Alexandrides T Achimastos A Ganotakis E Bilianou E Karagiannis A Liberopoulos EN Tziomalos K Mikhailidis DP;Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes 《Angiology》2012,63(5):358-366
This post hoc analysis of the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) study assesses the 3? year incidence of new-onset diabetes (NOD) and related cardiovascular disease (CVD) events in patients with metabolic syndrome (MetS), after multifactorial (lifestyle and drug, including atorvastatin) intervention. Patients were randomized to group A (low-density lipoprotein cholesterol [LDL-C] target < 100 mg/dL) and group B (< 130 mg/dL). The incidence of NOD during the 42-month follow-up was very low, 0.83 to 1.00/100 patient-years in patients with MetS and MetS with impaired fasting glucose, respectively. Older age, increased waist circumference, and persistent MetS were determinants of NOD. One CVD nonfatal event occurred in the 28 patients with NOD. Our findings suggest that treating the characteristics of MetS is achievable and beneficial. New-onset diabetes incidence and CVD events were negligible and not different from what is expected in the general population. 相似文献
20.